FHTX - CIK 0001822462
The table below shows Foghorn Therapeutics Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $80.88M | $55.45M | $80.34M | $52.21M | $101.14M | $92.80M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $163.24M |
| $249.60M |
| $240.18M |
| $351.40M |
| $459.56M |
| $190.69M |
| Property, plant & equipment | - | - | - | - | - | $19.53M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $198.10M | $283.98M | $285.92M | $404.88M | $519.77M | $255.59M |
| Accounts payable | $4.27M | $3.79M | $6.26M | $5.41M | $3.82M | $3.68M |
| Total current liabilities | $59.74M | $66.99M | $58.44M | $55.20M | $48.69M | $18.85M |
| Long-term debt | - | - | - | - | $0.00 | $19.65M |
| Total liabilities | $306.60M | $329.51M | $363.11M | $404.77M | $422.90M | $109.41M |
| Retained earnings | -$632.47M | -$558.18M | -$471.56M | -$373.14M | -$264.26M | -$162.94M |
| Total equity | -$108.50M | -$45.53M | -$77.19M | $112.00K | $96.87M | $146.19M |